OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Titel:
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Auteur:
Robson, M.E. Tung, N. Conte, P. Im, S.-A. Senkus, E. Xu, B. Masuda, N. Delaloge, S. Li, W. Armstrong, A. Wu, W. Goessl, C. Runswick, S. Domchek, S.M.